

RedHill announces launch of Talicia in UAE to treat bacterial infection

21 August 2024 | News

Talicia is the leading branded first-line therapy prescribed by US gastroenterologists for the treatment of *H. pylori*



RedHill Biopharma, a US-based specialty biopharmaceutical company, has announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE), making it available by prescription to treat adults with *Helicobacter pylori* (*H. pylori*) infection.

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat *H. pylori*.

H. pylori is a bacterial infection that affects approximately 35% of the U.S. population, with an estimated two million patients treated annually. Worldwide, more than 50% of the population has *H. pylori* infection, which is classified by the WHO as a Group 1 carcinogen.

Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the US FDA for the treatment of *H. pylori* infection in adults.